




STATE OF WEST VIRGINIA



PUBLIC EMPLOYEES INSURANCE AGENCY

Fiscal Year 2021

Detailed Medical and Prescription Drugs Claim Trend Report

Report Date: December 2021

YOUR ACTUARIES FOR THE LONG-TERM!

TABLE OF CONTENTS

OVERVIEW	1
KEY FINDINGS	2
METHODOLOGY	6
TREND COMPARISON USING ALLOWED VERSUS PAID METHODOLOGY	8
TOP 5 CATEGORIES	9
SUMMARY	9
TOTAL NON-MEDICARE TREND	11
NON-MEDICARE 24-MONTH TREND	12
NON-MEDICARE 36-MONTH TREND	13
NON-MEDICARE 48-MONTH TREND	14
NON-MEDICARE 12-MONTH IN STATE VERSUS OUT OF STATE CLAIMS	15
NON-MEDICARE PRESCRIPTION DRUGS TREND	16
Appendix A:	
Non-Medicare Medical Coverages – Cost Per Service, Utilization, Incurred PMPM Trends	
Appendix B	
Non-Medicare Prescription Drugs Coverages - Cost Per Service, Utilization, Incurred PMPM Trends	
Appendix C:	
Analysis of Top Forty Drugs Indicators	

West Virginia Public Employees Insurance Agency Report of Independent Actuary

Fiscal Year 2021 Detailed Medical & Prescription Drugs Claim Trend Report

OVERVIEW

Continuing Care Actuaries was engaged by the West Virginia Public Employees Insurance Agency (“PEIA”) to assist the Finance Board in monitoring the plan experience for fiscal year ending June 30, 2021 on a quarterly basis and the forecasting of Fiscal Years 2022 through 2026. This annual trend report to the Finance Board generally serves as the basis for projecting medical and drugs claims through Fiscal Year 2026 in the development of the Financial Plan to be approved by the PEIA Finance Board in December 2021. This report is intended for the sole use of the Finance Board and management team. Any other use requires written approval by Continuing Care Actuaries.

Continuing Care Actuaries has collected and reviewed the medical and drugs claims experience using Allowed Non-Medicare claims incurred and paid through June 2021. Effective July 1, 2012, West Virginia Retiree Health Benefit Trust Fund (“Trust Fund” or “RHBT”) had contracted with Humana to provide a Medicare Advantage Plan (“Humana MAPD”) benefit to Medicare-eligible retired employees and their Medicare-eligible dependents. Under this arrangement, Humana has assumed the financial risk of providing comprehensive medical and drugs. Non-Medicare retirees will continue enrollment in PEIA's Preferred Provider Benefit or the Managed Care Option.

While the majority of Medicare coverages are transferred to Humana, all newly eligible Medicare enrollees are initially covered by the RHBT on a secondary self-insured basis with Medicare being the primary coverage. These Medicare coverages are transferred in the following January from a self-insured secondary basis by RHBT to the Humana MAPD plan. While Continuing Care Actuaries monitors the cost trends of these Medicare coverages, we have not reviewed the Medicare claims experience in this report. This is due to relatively small number of these Medicare coverages and the resulting lack of credibility of Medicare claims with RHBT as the secondary payor.

From July 1, 2000 to June 30, 2019, HealthSmart Holding Inc. (“HealthSmart”), was the administrator of the plan’s medical claims and has provided reports for both medical and prescription drugs claims. Effective July 1, 2019, administration was assumed by United Medical Resources Inc. (“UMR”). The analysis utilized claim data supplied from HealthSmart and UMR as a primary source of claims data for this report and PEIA has separately provided enrollment information.

Trends were developed by category for the 24-month, 36-month and 48-month credible periods ending June 2021. The analysis for medical claims do not include incurred claims for the months after June 2021. The claim experience for the months after June 2021 is largely non-credible as substantial reserves as part of the projected monthly incurred amount. The claim information supplied by HealthSmart and UMR for the purposes of this analysis was compared to PEIA’s general ledger system to ensure accuracy of aggregate reporting. Additionally, in an effort to

assure accuracy the claim information provided by HealthSmart and UMR used in this analysis was reconciled and balanced to the PEIA general ledger amounts as of June 2021.

KEY FINDINGS - MEDICAL

- The 24-month, 36-month and 48-month methodologies had various utilization and unit cost trends. Long-term methodologies are most likely to produce accurate future trends that will allow PEIA to develop a financially solvent Financial Plan over the required five-year projection period. It is noteworthy that the overall medical trend increased from 4.8% in last year's analysis to 10.7% in Fiscal Year 2021 using a 24-month study period, likely due to the pandemic's major impact on FY2020 claims. Using the 24-month analysis, PEIA experienced a 3.2% trend in utilization and a 7.3% trend in unit cost, resulting in an aggregate trend of 10.7%. The 36-month method resulted in a lower trend of 8.1% and the 48-month method resulted in a lower trend of 6.6%.

The results below illustrate the 24-month trend calculated since Fiscal Year 2002.

West Virginia PEIA Non-Medicare Total 24-Month Trend Analysis-Allowed Claims			
	<u>Utilization</u>	<u>Cost/Service</u>	<u>Total Trend</u>
2002	4.1%	3.6%	7.8%
2003	9.8%	-3.0%	6.5%
2004	11.7%	-6.8%	4.0%
2005	2.8%	-1.1%	1.7%
2006	2.9%	1.0%	4.0%
2007	7.2%	-2.0%	5.1%
2008	2.9%	3.9%	6.9%
2009	2.5%	2.6%	5.1%
2010	2.5%	1.8%	4.4%
2011	4.2%	3.5%	7.8%
2012	5.1%	0.1%	5.3%
2013	2.6%	-1.6%	0.9%
2014	-0.4%	4.5%	4.1%
2015	0.7%	5.6%	6.3%
2016	8.6%	-0.7%	7.9%
2017	3.9%	-1.1%	2.8%
2018	4.4%	2.4%	6.9%
2019	5.5%	3.0%	8.6%
2020	3.2%	1.6%	4.8%
2021	3.2%	7.3%	10.7%

- In addition to studying trends on a 24, 36, and 48-month basis, CCA also looked at the trends for claims In-State and Out-of-State. Out-of-State claims were further divided into Border Counties ("OOS BC") and Non-Border Counties ("OOS NBC") as there are different cost sharing provisions in the PPB plans for services provided in Out-of-State Border Counties and Non-Border Counties.

- Overall PEIA and RHBT Fiscal Year 2021 24-month detail trends are summarized below. Note that these trends have not been adjusted for any changes in the plan benefit design:

Fiscal Year 2021 Claim Type	Medical	Drugs
PEIA – Active Local	20.7%	16.0%
PEIA – State	8.1%	12.4%
PEIA – Total	10.7%	13.1%
RHBT – Non-Medicare	11.9%	6.8%
Grand Total	10.8%	12.4%


- In the 24-month analysis, OOS BC services have experienced higher trends than In-State and OOS NBC services for Non-Medicare coverages in three out of four categories (HO, PS and O, not HI). A comparison of Non-Medicare medical trends for In-State claims versus OOS NBC claims versus OOS BC claims over the 24-month period analysis reveals an aggregate In-State trend of 15.9%, an aggregate OOS NBC trend of 1.3%, and an aggregate OOS BC trend of 28.2%.

The In-State utilization trend has been lower while the In-State cost per service trend has been higher compared to OOS NBC and OOS BC trends. The In-State utilization trend for Non-Medicare was 2.8%, while the OOS NBC trend was 9.9% and the OOS BC trend was 19.8%. The In-State cost per service trend for Non-Medicare was 12.8%, while the OOS NBC trend was -7.8%, and the OOS BC trend was 7.0%.

Within the In-State medical categories, the 3 highest trend subcategories were observed for Hospital Inpatient's Medical / Surgical, Physician Services' Anesthesia, and Physician Services' Psychiatric / Substance Abuse categories. These categories experienced high trends of 45.7%, 57.2% and 34.6%, respectively.

- Using the 24-month analysis, Hospital Inpatient services ("HI") represent 16.3% of all medical services and experienced a total trend of 3.8%. The overall trend was the product of a 5.9% increase in utilization and an -1.9% decrease in unit cost. In-State HI claims had a 40.8% overall trend, while OOS NBC HI claims experienced a -22.3% overall trend, and OOS BC HI claims experienced a 34.0% overall trend.
- Using the 24-month analysis, Hospital Outpatient services ("HO") represent 34.8% of all medical services and experienced the least favorable trend of the broader claim categories with a total trend of 7.3%. The overall trend was the product of a -3.7% decrease in utilization and an 11.4% increase in unit cost. In-State HO claims had a 7.5% overall trend, while OOS NBC HO claims experienced an 1.8% overall trend, and OOS BC HO claims experienced a 28.6% overall trend.

- Using the 24-month analysis, Physician Services (“PS”) represent 47.5% of all medical services and experienced a total trend of 15.5%. The overall trend was the product of a 7.7% increase in utilization of these services and a 7.3% increase in unit cost. In-State PS claims had a 16.7% overall trend, while OOS NBC PS claims experienced a 19.6% overall trend, and OOS BC PS claims experienced a 23.4% overall trend.
- Using the 24-month analysis, Other services (“O”), which are services that are principally Ambulance and Durable Medical Services, represent 1.5% of all medical services and experienced a total trend of 3.3%. The overall trend was the product of an -8.4% decrease in utilization of these services and a 12.8% increase in unit cost. In-State O claims showed an 1.9% overall trend, while OOS NBC O claims experienced a 7.1% overall trend, and OOS BC O claims experienced a 23.6% overall trend.
- As noted above, the OOS NBC trends were generally more favorable than the In-State trends and the OOS BC trends. This is contrary to last year’s report that the In-State trends were more favorable. However, last year’s results were an anomaly, as the Out-of-State trends have been historically better than the In-State trends.
- A component of the cost per service trend for hospital inpatient is the length of stay, or intensity. The chart below shows the average length of stay by number of days over the last four years. Over the 48-month analysis, the intensity for Non-Medicare hospital stays has an annual trend of -1.4%, which is comparable to -3.5% last year. The historical data is illustrated in the chart below. The increases in January through June 2019 are likely due to delayed claims processing from the change in TPAs.



The table below presents the overall Non-Medicare Hospital Inpatient trend showing the three components of visits, days per visit, and cost per day.

West Virginia PEIA Non-Medicare Hospital Inpatient Trend Analysis			
	<u>24-Month</u>	<u>36-Month</u>	<u>48-Month</u>
Visits	-10.2%	1.2%	-2.0%
Intensity	0.9%	-8.4%	-1.4%
<u>Cost/Day</u>	<u>14.6%</u>	<u>14.0%</u>	<u>4.1%</u>
Total	3.8%	5.7%	0.5%

Continuing Care Actuaries has included an additional analysis of utilization and cost on an incurred basis over the last 12 months. This analysis can be found on Page 14 and analyzes the distribution of services based on services provided in West Virginia and services provided elsewhere.

In the 12-month period ending June 2021, 85.8% of medical services were provided in the State of West Virginia, 10.6% of services were provided OOS NBC, and 3.6% of services were provided OOS BC. From a cost perspective, 73.1% of allowed charges were incurred In-State, 19.3% of allowed charges were provided OOS NBC, and 7.6% of allowed charges were provided OOS BC, illustrating the higher cost and intensity of the out-of-state and border county services.

By major medical category, 83.2% of Hospital Inpatient services were provided in the State of West Virginia representing 55.1% of the total allowed charges for Hospital Inpatient. Conversely, 11.8% of Hospital Inpatient services were provided OOS NBC and those charges represented 35.1% of the total allowed charges for Hospital Inpatient. In addition, 5.0% of Hospital Inpatient services were provided OOS BC and those charges represented 9.8% of the total allowed charges for Hospital Inpatient.

By major medical category, 92.3% of Hospital Outpatient services were provided in the State of West Virginia representing 75.9% of the total allowed charges for Hospital Outpatient. Conversely, 4.7% of Hospital Outpatient services were provided OOS NBC and those charges represented 13.2% of the total allowed charges for Hospital Outpatient. In addition, 3.0% of Hospital Outpatient services were provided OOS BC and those charges represented 10.8% of the total allowed charges for Hospital Outpatient.

By major medical category, 84.9% of Physician Services were provided in the State of West Virginia representing 77.7% of the total allowed charges for Physician Services. Conversely, 11.5% of Physician Services were provided OOS NBC and those charges represented 17.7% of the total allowed charges for Physician Services. In addition, 3.6% of Physician Services were provided OOS BC and those charges represented 4.6% of the total allowed charges for Physician Services.

By major medical category, 84.6% of Other Services were provided in the State of West Virginia representing 69.6% of the total allowed charges for Other Services. Conversely, 12.7% of Other Services were provided OOS NBC and those charges represented 27.8% of the total allowed charges for Other Services. In addition, 2.7% of Other Services were provided OOS BC and those charges represented 2.5% of the total allowed charges for Other Services.

KEY FINDINGS - DRUGS

Overall, gross prescription drugs trends for Non-Medicare coverages have decreased slightly compared to 14.4% last year. Using the 24-month analysis, there was a 0.3% utilization increase and a 12.8% prescription cost increase, resulting in an aggregate trend of 13.1% when adjusting for membership exposure. The 24-month overall trend is lower than the 36-month trend of 13.8%, and lower than the 48-month trend of 18.5%.

West Virginia PEIA Prescription Drugs Total 24-Month Trend Analysis-Allowed Claims			
	<u>Utilization</u>	<u>Cost/Prescription</u>	<u>Total Trend</u>
FY 2021	0.3%	12.8%	13.1%

METHODOLOGY

HealthSmart and UMR provided allowed and paid claim information for Non-Medicare and Medicare eligibility from July 2001 through August 2021. This data set was analyzed for Non-Medicare claims that were incurred from July 2017 through June 2021 in the 48-month credible period. The claim data was consolidated into 23 categories for Hospital Inpatient, Hospital Outpatient, Physician Services, and Other. In addition, claim experience was analyzed based on the state of service as defined by HealthSmart and UMR. HealthSmart and UMR provides the information based on the location that the service was performed, rather than the billing location of the provider. Continuing Care Actuaries verified that the HealthSmart and UMR information balanced in total to previously produced claim lag reports that PEIA personnel have balanced to the PEIA ledger accounts.

The trend analysis includes assumptions with respect to the completeness of the claim information to reflect and adjust for unreported claims. There was no adjustment to reflect the various reductions and changes in benefit design as affected by the Finance Board over the analysis period, such as an increase in hospital inpatient reimbursement rates. In developing aggregate claim trends, individual claim categories were weighted by claims paid for each category over the last 24, 36 and 48 months, respectively. The following charts summarize the amount of allowed dollars by category for each paid fiscal year.

The calculated trends for utilization, unit cost and in aggregate were based on a least squares methodology in defining the regression trend line. These trend lines were manually adjusted when the results appeared to be less credible.

Consistent with prior reports, the trends published in this report for Non-Medicare medical claims are based on the allowed amount in order to neutralize the impact of deductibles and copayments that have a varying impact on paid amounts in various months of the year. Paid claim trends are typically higher over the study period when cost-sharing provisions of the plan do not increase in the most recent Plan Year.

A summary of the annual Non-Medicare data provided by HealthSmart and UMR by Hospital Inpatient (HI), Hospital Outpatient (HO), Physician Services (PS), and Other Services (O) is detailed below.

<u>Non-Medicare Claims</u>	<u>FY2018</u>	<u>FY2019</u>	<u>FY2020</u>	<u>FY2021</u>
Hospital Inpatient	\$106,956,643	\$102,672,575	\$92,140,309	\$114,614,708
Hospital Outpatient	177,392,004	188,547,649	196,641,696	244,720,461
Physician Services	254,522,911	257,641,860	248,711,797	322,215,860
Other Services	22,176,304	23,069,154	22,845,028	28,500,419
Total	\$561,047,862	\$571,931,238	\$560,338,831	\$710,051,448

Certain categories in the data provided by HealthSmart and UMR were consolidated to produce the following summary table for Non-Medicare claims.

<u>Non-Medicare Claims</u>	<u>FY2018</u>	<u>FY2019</u>	<u>FY2020</u>	<u>FY2021</u>
HI Maternity	\$8,385,821	\$6,813,102	\$7,628,064	\$8,467,621
HI Medical/Surgical	95,197,843	92,184,805	81,899,886	102,741,808
HI Psychiatric/Substance Abuse	3,372,978	3,674,668	2,612,358	3,405,279
HO Emergency Room	32,163,606	33,007,592	31,186,804	33,755,261
HO Medical/Surgical	84,815,252	87,679,974	86,931,602	113,624,551
HO Other Services	59,564,684	66,763,971	77,009,372	95,190,449
HO Psychiatric/Substance Abuse	848,462	1,096,111	1,513,919	2,150,199
PS Anesthesia	11,365,283	11,110,846	10,846,644	15,736,005
PS Chemotherapy/Radiation	2,940,888	2,690,918	2,292,280	2,320,201
PS Emergency Room	5,841,468	5,849,755	5,266,138	5,763,296
PS Immunizations/Allergy	8,015,504	9,436,647	8,709,990	9,955,758
PS Inpatient Surgery	7,821,150	7,110,666	6,354,690	7,875,561
PS Inpatient Visits	7,240,434	6,941,150	6,306,005	8,539,514
PS Lab & Pathology	14,778,776	14,169,140	11,321,505	13,509,086
PS Maternity	6,967,876	6,745,198	7,584,983	9,374,716
PS Office Visits	67,770,616	66,361,796	59,116,352	75,267,020
PS Other Services	72,876,421	77,346,268	83,662,691	111,876,733
PS Outpatient Surgery	24,568,548	24,361,219	21,530,089	26,811,354
PS Psychiatric/Substance Abuse	12,927,048	13,987,187	14,883,476	21,863,964
PS Radiology	11,408,900	11,531,069	10,836,956	13,322,652
PS Therapy/Rehab	13,421,383	14,372,906	14,285,497	18,562,338
O Ambulance	4,773,681	4,835,293	4,321,911	4,715,448
O Durable Medical Equipment	3,981,240	3,860,955	4,237,621	5,222,633

TREND COMPARISON USING ALLOWED VERSUS PAID METHODOLOGY

The trend analysis has been developed throughout the report on an allowed basis for Non-Medicare claims to neutralize the impact of deductibles and co-payments that have a varying impact on paid amounts depending on the month of the year.

We have examined the trends utilizing paid claims as opposed to allowed claims. The following table summarizes the trends on a paid basis for the Fiscal Years 2018 through 2021 and on an allowed basis for Non-Medicare medical claims. This exercise is important since interim monthly trend updates provided to PEIA throughout the year are based on paid claims.

West Virginia PEIA Non-Medicare Medical Total Trend Analysis		
	<u>Paid Basis</u>	<u>Allowed Basis</u>
24-Month Trend	21.6%	10.7%
36-Month Trend	10.5%	8.1%
48-Month Trend	8.1%	6.6%

TOP 5 CATEGORIES

The following tables give detail on the top 5 increases by utilization, cost per service, and cost per capita using the 24-month analysis. Notably, O-Appliances (DME) experienced the highest increase in utilization. HO-Psychiatric / Substance Abuse experienced the highest increase in cost per service and in cost per capita.

Top 5 Highest Percentage in Utilization Increases			
	2020 Average	2021 Average	Top 5
Category	Utilization	Utilization	Highest %
PS-Anesthesia	0.02448	0.04152	69.6%
PS- Maternity	0.01787	0.02139	19.7%
PS- Outpatient Surgery	0.06819	0.07951	16.6%
HO-Psychiatric / Substance Abuse	0.00283	0.00323	14.2%
PS-Psychiatric / Substance Abuse	0.08657	0.09808	13.3%

Top 5 Highest Percentage in Cost / Service Increases			
	2020 Average	2021 Average	Top 5
Category	Cost / Service	Cost / Service	Highest %
O- Durable Medical Equipment	\$130.21	\$163.11	25.3%
PS-Immunizations/Allergy	85.27	103.72	21.6%
PS-Psychiatric / Substance Abuse	90.11	107.39	19.2%
HI- Maternity	1,492.15	1,759.16	17.9%
HO-Medical / Surgical	597.41	685.25	14.7%

Top 5 Highest Percentage in Cost / Capita Increases			
	2020 Average	2021 Average	Top 5
Category	Cost / Capita	Cost / Capita	Highest %
PS-Psychiatric / Substance Abuse	\$7.80	\$10.53	35.0%
HO-Psychiatric / Substance Abuse	0.84	1.06	26.8%
PS-Anesthesia	6.14	7.72	25.6%
O- Durable Medical Equipment	2.18	2.59	18.6%
HO-Medical / Surgical	47.11	55.16	17.1%

SUMMARY

The following tables and sections summarize the information and findings of the trend analysis. The tables and charts on the next several pages include separate analysis of utilization and unit cost trends for Non-Medicare coverages. The charts show the breakdown between the different study periods and for In-State, OOS NBC, and OOS BC.

Recent experience has shown that the Non-Medicare medical claim trends are higher than the current trend assumption of 6.0% for FY 2022. Additionally, the 24-Month trend has reflected a higher 10.7% trend for medical, while the 36-month trend is 8.1% and the 48-month trend is 6.6%. CCA believes that it is appropriate to retain the FY 2022 medical claim trend assumption for Non-Medicare medical at 6.0%, given the long-term trend experience after adjustment for the post COVID high trend periods to pre COVID utilization levels.

Additionally, recent experience has shown that Non-Medicare gross drugs claim trends are similar to the current trend assumption of 13.5% for FY 2022. The 24-Month trend has reflected a 13.1% trend for drugs, before rebates. It should be noted that the 36-month trend is 13.8% and the 48-month trend is 18.5%. CCA believes that it is appropriate to retain the FY 2022 prescription drugs claim trend assumption for Non-Medicare prescription drugs at 13.5%. This approximates the 24-month and 36-month trend experience which matches the time period that the current PBM has been in place.

The update of the trend assumptions for FY 2022 is shown below.

	Fiscal Year 2022 Trends		
Claim Type	Previous Assumption	Updated Assumption	Change
Non-Medicare – Medical	6.0%	6.0%	0.0%
Non-Medicare – Gross Prescription Drugs	13.5%	13.5%	0.0%

In the past, claim trends for the financial plan included a 0.5% margin in future years. CCA has assumed the drugs claim trends for the financial projection will increase by 0.5% in FY 2023 and in each successive fiscal year. Medical trends are assumed to increase 1.0% in FY 2023, and then 0.5% thereafter. Additionally, drug rebates have been trending at approximately 30% over the last two years. As a result, CCA has separated net drugs in the financial plan into gross drugs and drug rebate amounts. Drug rebates trends are set at 15% in the financial plan.

We will continue to monitor the claim trend experience and incorporate changes as necessary throughout the fiscal year based on the relatively volatile nature of recent trend experience at PEIA.

Respectfully,



Dave Bond, F.S.A., F.C.A., M.A.A.A.

Managing Partner



Chris Borcik, F.S.A., F.C.A., M.A.A.A.

Principal

**West Virginia PEIA Non-Medicare Total
Study Period of July 2017 to June 2021
(Allowed Claims)**

Trends Summary - Excludes Drugs

	24 Month Trends Summary				36 Month Trends Summary				48 Month Trends Summary			
	<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>	<u>Weight</u>	<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>	<u>Weight</u>	<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>	<u>Weight</u>
HOSPITAL INPATIENT												
Maternity	-5.0%	17.9%	12.0%	1.3%	2.5%	10.1%	12.9%	1.2%	3.5%	0.0%	3.5%	1.3%
Medical / Surgical	7.2%	-3.9%	3.0%	14.5%	6.6%	-1.1%	5.4%	15.0%	0.9%	-0.5%	0.4%	15.5%
Psychiatric / Substance Abuse	-5.9%	5.1%	-1.1%	0.5%	5.0%	-8.1%	-3.6%	0.5%	0.0%	-2.8%	-2.8%	0.5%
TOTAL	5.9%	-1.9%	3.8%	16.3%	6.2%	-0.5%	5.7%	16.8%	1.1%	-0.5%	0.5%	17.4%
HOSPITAL OUTPATIENT												
Emergency Room	-22.8%	14.4%	-11.7%	5.1%	-8.8%	6.5%	-2.9%	5.3%	-4.8%	5.2%	0.1%	5.4%
Medical / Surgical	2.1%	14.7%	17.1%	15.8%	10.6%	-0.2%	10.4%	15.6%	11.4%	-2.2%	8.9%	15.5%
Other Services	-3.7%	6.5%	2.6%	13.6%	5.7%	7.5%	13.7%	13.0%	5.8%	9.4%	15.7%	12.4%
Psychiatric / Substance Abuse	14.2%	11.1%	26.8%	0.3%	16.7%	15.3%	34.5%	0.3%	15.2%	17.5%	35.3%	0.2%
TOTAL	-3.7%	11.4%	7.3%	34.8%	5.8%	3.9%	9.9%	34.2%	6.7%	3.4%	10.3%	33.6%
PHYSICIAN SERVICES												
Anesthesia	69.6%	-25.9%	25.6%	2.1%	31.4%	-12.1%	15.4%	2.0%	16.8%	-7.2%	8.3%	2.0%
Chemotherapy / Radiation	-19.0%	6.6%	-13.7%	0.4%	-9.0%	0.3%	-8.7%	0.4%	-4.1%	-4.5%	-8.4%	0.4%
Emergency Room	-10.5%	5.4%	-5.6%	0.9%	-9.3%	4.0%	-5.7%	0.9%	-5.5%	2.8%	-2.9%	0.9%
Immunizations / Injections / Allergy	-28.3%	21.6%	-12.8%	1.5%	-16.0%	12.8%	-5.3%	1.5%	-6.4%	10.4%	3.3%	1.5%
Inpatient Surgery	-0.3%	8.2%	7.9%	1.1%	1.3%	-1.1%	0.1%	1.2%	-0.1%	-1.8%	-1.9%	1.2%
Inpatient Visits	10.2%	5.7%	16.5%	1.2%	5.3%	0.9%	6.2%	1.2%	3.9%	-0.9%	2.9%	1.2%
Lab & Pathology	2.8%	2.6%	5.4%	2.0%	-0.4%	-5.4%	-5.8%	2.1%	-0.9%	-4.4%	-5.3%	2.2%
Maternity	19.7%	-5.3%	13.3%	1.3%	15.8%	-2.5%	12.9%	1.3%	10.8%	-1.2%	9.5%	1.3%
Office Visits	0.6%	13.8%	14.5%	10.6%	-1.1%	4.0%	2.8%	10.9%	-0.9%	2.0%	1.1%	11.2%
Other Services	6.4%	8.7%	15.6%	15.4%	6.5%	7.5%	14.4%	14.8%	5.9%	7.0%	13.3%	14.3%
Outpatient Surgery	16.6%	-1.7%	14.6%	3.8%	9.5%	-5.8%	3.2%	4.0%	6.2%	-4.2%	1.8%	4.1%
Psychiatric / Substance Abuse	13.3%	19.2%	35.0%	2.9%	14.2%	5.9%	20.9%	2.7%	13.9%	2.5%	16.7%	2.6%
Radiology	2.9%	4.4%	7.4%	1.9%	-1.9%	4.4%	2.4%	1.9%	0.1%	2.5%	2.6%	2.0%
Therapies	8.3%	3.7%	12.4%	2.6%	5.3%	2.6%	8.0%	2.6%	6.1%	1.9%	8.1%	2.5%
TOTAL	7.7%	7.3%	15.5%	47.5%	4.7%	3.1%	7.9%	47.5%	3.9%	2.3%	6.3%	47.6%
OTHER												
Ambulance	-11.7%	-0.2%	-11.9%	0.7%	-3.0%	-5.8%	-8.6%	0.8%	0.0%	-4.1%	-4.1%	0.8%
Appliances (DME)	-5.3%	25.3%	18.6%	0.7%	5.3%	8.2%	13.9%	0.7%	2.6%	6.8%	9.6%	0.7%
TOTAL	-8.4%	12.8%	3.3%	1.5%	1.1%	1.0%	2.1%	1.5%	1.2%	1.2%	2.4%	1.5%
GRAND TOTAL	3.2%	7.3%	10.7%	100.0%	5.3%	2.7%	8.1%	100.0%	4.3%	2.2%	6.6%	100.0%

**West Virginia PEIA Non-Medicare Total
Study Period of July 2019 to June 2021
(Allowed Claims)**

24 Month Trends Summary - Excludes Drugs

	In-State			OOS NBC			OOS BC			Total			In-State	OOS NBC	OOS BC	Total
	Utilization	Cost / Service	Total Trend	Utilization	Cost / Service	Total Trend	Utilization	Cost / Service	Total Trend	Utilization	Cost / Service	Total Trend	Weight	Weight	Weight	Weight
HOSPITAL INPATIENT																
Maternity	-2.1%	10.9%	8.6%	-35.1%	102.6%	31.4%	-3.1%	7.7%	4.4%	-5.0%	17.9%	12.0%	1.2%	1.1%	2.2%	1.3%
Medical / Surgical	7.9%	35.0%	45.7%	-3.5%	-23.6%	-26.3%	29.3%	4.3%	34.9%	7.2%	-3.9%	3.0%	9.7%	30.4%	19.3%	14.5%
Psychiatric / Substance Abuse	-6.5%	38.9%	29.9%	-1.0%	26.1%	24.9%	72.5%	-23.0%	32.9%	-5.9%	5.1%	-1.1%	0.5%	0.4%	0.3%	0.5%
TOTAL	6.2%	32.6%	40.8%	-4.6%	-18.6%	-22.3%	28.7%	4.1%	34.0%	5.9%	-1.9%	3.8%	11.5%	31.9%	21.7%	16.3%
HOSPITAL OUTPATIENT																
Emergency Room	-23.1%	10.2%	-15.2%	-38.6%	53.4%	-5.8%	5.9%	1.7%	7.7%	-22.8%	14.4%	-11.7%	5.0%	3.3%	11.7%	5.1%
Medical / Surgical	0.8%	15.1%	16.1%	13.3%	1.5%	15.0%	25.4%	10.5%	38.6%	2.1%	14.7%	17.1%	16.9%	9.5%	22.0%	15.8%
Other Services	-4.2%	9.6%	5.0%	-1.6%	-11.0%	-12.4%	10.9%	14.7%	27.2%	-3.7%	6.5%	2.6%	14.0%	11.5%	14.7%	13.6%
Psychiatric / Substance Abuse	18.8%	11.4%	32.4%	-16.2%	18.2%	-0.9%	-12.8%	-15.6%	-26.4%	14.2%	11.1%	26.8%	0.3%	0.2%	0.1%	0.3%
TOTAL	-4.2%	12.3%	7.5%	-0.9%	2.7%	1.8%	15.7%	11.1%	28.6%	-3.7%	11.4%	7.3%	36.2%	24.4%	48.6%	34.8%
PHYSICIAN SERVICES																
Anesthesia	112.9%	-26.2%	57.2%	63.8%	-26.9%	19.8%	59.6%	-13.8%	37.6%	69.6%	-25.9%	25.6%	2.2%	1.9%	1.4%	2.1%
Chemotherapy / Radiation	-20.6%	3.3%	-18.1%	-3.1%	16.7%	13.2%	-2.0%	4.0%	2.0%	-19.0%	6.6%	-13.7%	0.4%	0.2%	0.4%	0.4%
Emergency Room	-9.0%	2.7%	-6.6%	-33.7%	16.0%	-23.1%	6.6%	20.0%	27.9%	-10.5%	5.4%	-5.6%	0.9%	0.6%	1.3%	0.9%
Immunizations / Injections / Allergy	-28.3%	20.9%	-13.4%	-32.2%	25.2%	-15.1%	-16.0%	27.4%	7.1%	-28.3%	21.6%	-12.8%	1.8%	0.5%	0.8%	1.5%
Inpatient Surgery	-4.2%	7.8%	3.3%	17.5%	6.0%	24.4%	34.4%	-14.0%	15.6%	-0.3%	8.2%	7.9%	1.1%	1.5%	0.4%	1.1%
Inpatient Visits	10.4%	3.7%	14.4%	2.3%	11.6%	14.1%	38.8%	9.3%	51.7%	10.2%	5.7%	16.5%	1.2%	1.3%	0.6%	1.2%
Lab & Pathology	0.6%	-3.6%	-3.0%	7.2%	7.0%	14.7%	4.5%	-0.3%	4.1%	2.8%	2.6%	5.4%	1.2%	5.1%	0.9%	2.0%
Maternity	12.7%	-2.4%	10.0%	38.5%	-11.8%	22.2%	11.8%	18.0%	31.9%	19.7%	-5.3%	13.3%	1.3%	1.6%	0.6%	1.3%
Office Visits	0.2%	13.9%	14.1%	6.6%	14.1%	21.7%	3.7%	9.0%	13.1%	0.6%	13.8%	14.5%	13.1%	3.3%	5.9%	10.6%
Other Services	0.6%	13.8%	14.5%	41.5%	-18.0%	16.0%	14.1%	10.1%	25.7%	6.4%	8.7%	15.6%	14.2%	21.6%	10.3%	15.4%
Outpatient Surgery	16.2%	-2.1%	13.7%	16.3%	2.5%	19.3%	27.5%	-5.1%	21.0%	16.6%	-1.7%	14.6%	4.4%	2.0%	3.1%	3.8%
Psychiatric / Substance Abuse	14.5%	17.5%	34.6%	-2.7%	47.0%	43.0%	25.7%	8.0%	35.7%	13.3%	19.2%	35.0%	3.7%	0.8%	0.6%	2.9%
Radiology	2.8%	3.2%	6.1%	-1.4%	10.8%	9.3%	14.9%	2.6%	17.9%	2.9%	4.4%	7.4%	2.1%	1.1%	2.2%	1.9%
Therapies	7.9%	3.5%	11.7%	7.7%	19.3%	28.5%	19.9%	5.7%	26.7%	8.3%	3.7%	12.4%	3.4%	0.2%	0.9%	2.6%
TOTAL	7.4%	8.7%	16.7%	27.8%	-6.4%	19.6%	16.0%	6.4%	23.4%	7.7%	7.3%	15.5%	51.0%	41.7%	29.2%	47.5%
OTHER																
Ambulance	-12.0%	1.0%	-11.1%	-11.7%	-4.5%	-15.6%	-5.1%	-13.2%	-17.6%	-11.7%	-0.2%	-11.9%	0.7%	0.9%	0.4%	0.7%
Appliances (DME)	-8.1%	25.6%	15.4%	11.5%	13.4%	26.5%	20.2%	33.7%	60.6%	-5.3%	25.3%	18.6%	0.7%	1.1%	0.1%	0.7%
TOTAL	-10.1%	13.3%	1.9%	1.4%	5.6%	7.1%	9.2%	13.2%	23.6%	-8.4%	12.8%	3.3%	1.4%	2.0%	0.5%	1.5%
GRAND TOTAL	2.8%	12.8%	15.9%	9.9%	-7.8%	1.3%	19.8%	7.0%	28.2%	3.2%	7.3%	10.7%	100.0%	100.0%	100.0%	100.0%

**West Virginia PEIA Non-Medicare Total
Study Period of July 2018 to June 2021
(Allowed Claims)**

36 Month Trends Summary - Excludes Drugs

	In-State			OOS NBC			OOS BC			Total			In-State	OOS NBC	OOS BC	Total
	Utilization	Cost / Service	Total Trend	Utilization	Cost / Service	Total Trend	Utilization	Cost / Service	Total Trend	Utilization	Cost / Service	Total Trend	Weight	Weight	Weight	Weight
HOSPITAL INPATIENT																
Maternity	1.3%	3.6%	4.9%	14.8%	4.1%	19.5%	3.8%	5.4%	9.5%	2.5%	10.1%	12.9%	1.2%	0.9%	2.1%	1.2%
Medical / Surgical	5.9%	10.2%	16.7%	9.6%	-13.4%	-5.1%	10.8%	2.9%	14.0%	6.6%	-1.1%	5.4%	9.9%	32.0%	20.0%	15.0%
Psychiatric / Substance Abuse	-1.5%	-3.8%	-5.3%	25.3%	-28.9%	-11.0%	31.1%	1.6%	33.2%	5.0%	-8.1%	-3.6%	0.6%	0.4%	0.3%	0.5%
TOTAL	5.0%	8.8%	14.3%	9.9%	-13.1%	-4.5%	10.9%	2.9%	14.1%	6.2%	-0.5%	5.7%	11.7%	33.3%	22.4%	16.8%
HOSPITAL OUTPATIENT																
Emergency Room	-10.0%	4.0%	-6.4%	-2.6%	6.2%	3.4%	5.9%	3.5%	9.7%	-8.8%	6.5%	-2.9%	5.3%	3.3%	11.7%	5.3%
Medical / Surgical	10.4%	-1.6%	8.7%	8.9%	-0.5%	8.4%	21.4%	6.7%	29.6%	10.6%	-0.2%	10.4%	16.8%	9.5%	20.9%	15.6%
Other Services	5.5%	8.7%	14.7%	9.9%	-7.2%	2.0%	9.3%	25.3%	37.0%	5.7%	7.5%	13.7%	13.3%	11.5%	13.2%	13.0%
Psychiatric / Substance Abuse	23.7%	32.7%	64.2%	-23.6%	-15.4%	-35.3%	-8.3%	-20.8%	-27.4%	16.7%	15.3%	34.5%	0.3%	0.2%	0.2%	0.3%
TOTAL	5.6%	3.4%	9.2%	7.5%	-2.9%	4.5%	13.4%	14.7%	30.1%	5.8%	3.9%	9.9%	35.7%	24.5%	45.9%	34.2%
PHYSICIAN SERVICES																
Anesthesia	34.5%	-11.7%	18.8%	34.5%	-19.7%	8.0%	26.1%	-4.0%	21.0%	31.4%	-12.1%	15.4%	2.2%	1.8%	1.4%	2.0%
Chemotherapy / Radiation	-10.1%	-1.0%	-10.9%	-0.5%	0.9%	0.4%	7.7%	-4.5%	2.9%	-9.0%	0.3%	-8.7%	0.4%	0.3%	0.4%	0.4%
Emergency Room	-10.7%	3.8%	-7.3%	1.7%	-11.4%	-9.9%	0.7%	4.2%	5.0%	-9.3%	4.0%	-5.7%	1.0%	0.6%	1.4%	0.9%
Immunizations / Injections / Allergy	-18.0%	13.4%	-7.0%	16.3%	-18.7%	-5.4%	-12.0%	18.0%	3.8%	-16.0%	12.8%	-5.3%	1.9%	0.4%	0.9%	1.5%
Inpatient Surgery	-0.1%	-2.9%	-3.0%	6.8%	2.7%	9.6%	12.2%	-9.0%	2.0%	1.3%	-1.1%	0.1%	1.1%	1.5%	0.4%	1.2%
Inpatient Visits	6.2%	0.3%	6.6%	-0.7%	4.3%	3.6%	15.4%	-4.8%	9.9%	5.3%	0.9%	6.2%	1.2%	1.3%	0.6%	1.2%
Lab & Pathology	-1.0%	-5.6%	-6.5%	0.0%	-3.8%	-3.8%	7.6%	-27.8%	-22.3%	-0.4%	-5.4%	-5.8%	1.3%	5.5%	1.1%	2.1%
Maternity	7.4%	-1.7%	5.6%	40.5%	2.3%	43.7%	23.6%	-9.8%	11.5%	15.8%	-2.5%	12.9%	1.3%	1.4%	0.6%	1.3%
Office Visits	-1.9%	4.3%	2.3%	11.1%	0.2%	11.3%	3.0%	-1.5%	1.4%	-1.1%	4.0%	2.8%	13.5%	3.2%	6.3%	10.9%
Other Services	2.4%	10.8%	13.4%	31.4%	-9.1%	19.5%	10.5%	-8.1%	1.6%	6.5%	7.5%	14.4%	13.7%	20.0%	11.1%	14.8%
Outpatient Surgery	9.0%	-5.8%	2.7%	13.4%	-6.5%	6.1%	15.1%	-9.2%	4.4%	9.5%	-5.8%	3.2%	4.5%	2.0%	3.3%	4.0%
Psychiatric / Substance Abuse	14.5%	5.8%	21.1%	10.3%	10.6%	22.0%	17.2%	-4.7%	11.7%	14.2%	5.9%	20.9%	3.5%	0.8%	0.6%	2.7%
Radiology	-2.8%	3.9%	1.0%	5.5%	4.2%	9.9%	5.5%	0.8%	6.3%	-1.9%	4.4%	2.4%	2.1%	1.1%	2.3%	1.9%
Therapies	4.7%	3.0%	7.8%	10.0%	-6.3%	3.1%	16.7%	0.9%	17.7%	5.3%	2.6%	8.0%	3.4%	0.3%	0.9%	2.6%
TOTAL	2.9%	4.1%	7.1%	21.0%	-6.0%	13.7%	10.7%	-9.3%	0.5%	4.7%	3.1%	7.9%	51.2%	40.2%	31.1%	47.5%
OTHER																
Ambulance	-6.7%	-7.3%	-13.6%	26.3%	-12.1%	10.9%	27.8%	-48.2%	-33.8%	-3.0%	-5.8%	-8.6%	0.8%	0.7%	0.4%	0.8%
Appliances (DME)	12.5%	16.9%	31.5%	-11.4%	-3.3%	-14.3%	-3.3%	37.2%	32.6%	5.3%	8.2%	13.9%	0.6%	1.3%	0.1%	0.7%
TOTAL	1.8%	3.4%	5.2%	2.5%	-6.6%	-4.2%	8.1%	5.8%	14.4%	1.1%	1.0%	2.1%	1.4%	2.0%	0.5%	1.5%
GRAND TOTAL	4.1%	4.4%	8.7%	13.6%	-7.6%	5.0%	11.4%	1.0%	12.5%	5.3%	2.7%	8.1%	100.0%	100.0%	100.0%	100.0%

**West Virginia PEIA Non-Medicare Total
Study Period of July 2017 to June 2021
(Allowed Claims)**

48 Month Trends Summary - Excludes Drugs

	In-State			OOS NBC			OOS BC			Total			In-State	OOS NBC	OOS BC	Total
	Utilization	Cost / Service	Total Trend	Utilization	Cost / Service	Total Trend	Utilization	Cost / Service	Total Trend	Utilization	Cost / Service	Total Trend	Weight	Weight	Weight	Weight
HOSPITAL INPATIENT																
Maternity	2.5%	4.0%	6.6%	23.3%	1.2%	24.8%	-2.5%	4.1%	1.4%	3.5%	0.0%	3.5%	1.2%	1.1%	2.5%	1.3%
Medical / Surgical	0.8%	7.2%	8.1%	1.6%	-4.1%	-2.5%	-0.8%	2.2%	1.5%	0.9%	-0.5%	0.4%	9.9%	33.3%	20.9%	15.5%
Psychiatric / Substance Abuse	-3.1%	0.7%	-2.4%	13.6%	-17.2%	-5.9%	-13.0%	13.7%	-1.0%	0.0%	-2.8%	-2.8%	0.6%	0.4%	0.4%	0.5%
TOTAL	0.8%	6.5%	7.4%	2.4%	-4.1%	-1.7%	-1.0%	2.4%	1.4%	1.1%	-0.5%	0.5%	11.8%	34.8%	23.8%	17.4%
HOSPITAL OUTPATIENT																
Emergency Room	-5.7%	3.6%	-2.2%	3.5%	0.8%	4.4%	0.9%	8.5%	9.5%	-4.8%	5.2%	0.1%	5.5%	3.2%	11.3%	5.4%
Medical / Surgical	11.7%	-3.1%	8.3%	6.4%	2.1%	8.6%	9.6%	8.0%	18.4%	11.4%	-2.2%	8.9%	16.8%	9.3%	20.2%	15.5%
Other Services	5.8%	10.7%	17.1%	9.8%	-1.4%	8.2%	0.8%	21.2%	22.2%	5.8%	9.4%	15.7%	12.8%	11.0%	12.4%	12.4%
Psychiatric / Substance Abuse	19.5%	34.5%	60.8%	-6.0%	-11.3%	-16.6%	-6.2%	-6.2%	-12.0%	15.2%	17.5%	35.3%	0.2%	0.2%	0.2%	0.2%
TOTAL	6.9%	3.2%	10.3%	7.5%	0.1%	7.6%	4.2%	14.0%	18.8%	6.7%	3.4%	10.3%	35.2%	23.8%	44.0%	33.6%
PHYSICIAN SERVICES																
Anesthesia	19.6%	-7.2%	11.0%	23.9%	-10.8%	10.4%	4.9%	-1.5%	3.3%	16.8%	-7.2%	8.3%	2.2%	1.8%	1.4%	2.0%
Chemotherapy / Radiation	-4.6%	-3.8%	-8.2%	-1.4%	-8.3%	-9.6%	4.5%	-9.0%	-4.9%	-4.1%	-4.5%	-8.4%	0.5%	0.3%	0.4%	0.4%
Emergency Room	-6.5%	2.8%	-3.8%	5.4%	-8.8%	-3.8%	-1.7%	4.3%	2.5%	-5.5%	2.8%	-2.9%	1.0%	0.6%	1.4%	0.9%
Immunizations / Injections / Allergy	-7.0%	11.4%	3.6%	11.1%	-13.1%	-3.5%	-12.3%	15.6%	1.4%	-6.4%	10.4%	3.3%	1.9%	0.4%	0.9%	1.5%
Inpatient Surgery	-0.1%	-3.3%	-3.5%	0.5%	3.5%	4.0%	-4.3%	-9.7%	-13.5%	-0.1%	-1.8%	-1.9%	1.2%	1.5%	0.5%	1.2%
Inpatient Visits	5.5%	-0.1%	5.4%	-2.8%	-1.4%	-4.1%	7.6%	-5.2%	2.0%	3.9%	-0.9%	2.9%	1.2%	1.4%	0.6%	1.2%
Lab & Pathology	-0.9%	-4.8%	-5.6%	-1.3%	-2.5%	-3.8%	1.8%	-19.0%	-17.6%	-0.9%	-4.4%	-5.3%	1.4%	5.7%	1.2%	2.2%
Maternity	4.6%	0.1%	4.7%	31.8%	0.2%	32.0%	16.1%	-15.2%	-1.5%	10.8%	-1.2%	9.5%	1.4%	1.2%	0.6%	1.3%
Office Visits	-1.4%	2.2%	0.8%	8.7%	0.0%	8.7%	-1.1%	-1.9%	-3.0%	-0.9%	2.0%	1.1%	14.0%	3.1%	6.4%	11.2%
Other Services	4.6%	7.9%	12.9%	11.4%	4.4%	16.3%	4.9%	-4.5%	0.2%	5.9%	7.0%	13.3%	13.4%	18.9%	11.2%	14.3%
Outpatient Surgery	6.0%	-3.6%	2.2%	8.7%	-6.8%	1.3%	7.5%	-9.0%	-2.2%	6.2%	-4.2%	1.8%	4.7%	2.1%	3.4%	4.1%
Psychiatric / Substance Abuse	14.0%	2.5%	16.9%	14.5%	4.9%	20.1%	5.1%	-3.4%	1.6%	13.9%	2.5%	16.7%	3.4%	0.7%	0.6%	2.6%
Radiology	-0.1%	2.3%	2.2%	3.9%	4.4%	8.5%	-1.3%	0.6%	-0.7%	0.1%	2.5%	2.6%	2.2%	1.1%	2.3%	2.0%
Therapies	5.8%	2.0%	8.0%	10.4%	-2.8%	7.4%	9.9%	4.1%	14.4%	6.1%	1.9%	8.1%	3.3%	0.2%	0.8%	2.5%
TOTAL	3.3%	2.7%	6.0%	9.1%	0.8%	10.0%	3.8%	-6.5%	-3.0%	3.9%	2.3%	6.3%	51.6%	39.2%	31.7%	47.6%
OTHER																
Ambulance	-2.9%	-6.6%	-9.3%	28.2%	-2.7%	24.7%	27.2%	-17.1%	5.5%	0.0%	-4.1%	-4.1%	0.8%	0.7%	0.4%	0.8%
Appliances (DME)	24.5%	11.7%	39.1%	-26.2%	17.2%	-13.5%	-5.6%	23.8%	16.8%	2.6%	6.8%	9.6%	0.5%	1.6%	0.1%	0.7%
TOTAL	7.8%	0.6%	8.5%	-9.6%	11.1%	0.4%	4.4%	11.3%	16.2%	1.2%	1.2%	2.4%	1.4%	2.2%	0.5%	1.5%
GRAND TOTAL	4.3%	3.3%	7.7%	6.0%	-0.8%	5.1%	2.2%	1.9%	4.2%	4.3%	2.2%	6.6%	100.0%	100.0%	100.0%	100.0%

**West Virginia PEIA Non-Medicare Total
Study Period of July 2020 to June 2021
(Allowed Claims)**

12 Month Summary - Excludes Drugs

	Number of Visits							Total Allowed Cost						
	<u>In-State</u>	<u>OOS NBC</u>	<u>OOS BC</u>	<u>Total</u>	<u>In-State %</u>	<u>OOS NBC %</u>	<u>OOS BC %</u>	<u>In-State</u>	<u>OOS NBC</u>	<u>OOS BC</u>	<u>Total</u>	<u>In-State %</u>	<u>OOS NBC %</u>	<u>OOS BC %</u>
HOSPITAL INPATIENT														
Maternity	4,420	298	281	4,999	88.4%	6.0%	5.6%	5,936,303	1,661,996	1,102,362	8,700,661	68.2%	19.1%	12.7%
Medical / Surgical	9,266	1,521	551	11,338	81.7%	13.4%	4.9%	55,506,685	38,837,833	10,237,957	104,582,475	53.1%	37.1%	9.8%
Psychiatric / Substance Abuse	697	231	28	955	73.0%	24.1%	2.9%	2,829,795	507,574	89,216	3,426,585	82.6%	14.8%	2.6%
TOTAL	14,383	2,049	860	17,292	83.2%	11.8%	5.0%	64,272,782	41,007,404	11,429,535	116,709,721	55.1%	35.1%	9.8%
HOSPITAL OUTPATIENT														
Emergency Room	31,548	2,220	2,339	36,107	87.4%	6.1%	6.5%	21,858,385	4,324,217	5,620,966	31,803,567	68.7%	13.6%	17.7%
Medical / Surgical	148,553	8,749	4,646	161,948	91.7%	5.4%	2.9%	83,161,177	12,537,595	11,744,951	107,443,723	77.4%	11.7%	10.9%
Other Services	266,445	11,450	7,712	285,608	93.3%	4.0%	2.7%	68,411,876	13,418,658	7,607,406	89,437,939	76.5%	15.0%	8.5%
Psychiatric / Substance Abuse	5,886	409	131	6,426	91.6%	6.4%	2.0%	1,792,907	194,639	47,685	2,035,231	88.1%	9.6%	2.3%
TOTAL	452,433	22,826	14,829	490,089	92.3%	4.7%	3.0%	175,224,345	30,475,109	25,021,008	230,720,462	75.9%	13.2%	10.8%
PHYSICIAN SERVICES														
Anesthesia	103,739	8,694	2,610	115,043	90.2%	7.6%	2.3%	11,386,420	2,611,984	678,097	14,676,502	77.6%	17.8%	4.6%
Chemotherapy / Radiation	27,913	1,749	1,535	31,197	89.5%	5.6%	4.9%	1,645,717	324,784	180,638	2,151,139	76.5%	15.1%	8.4%
Emergency Room	32,058	2,612	1,887	36,558	87.7%	7.1%	5.2%	3,957,189	708,915	690,962	5,357,065	73.9%	13.2%	12.9%
Immunizations / Injections / Allergy	107,676	7,859	3,431	118,966	90.5%	6.6%	2.9%	8,192,348	580,418	426,407	9,199,173	89.1%	6.3%	4.6%
Inpatient Surgery	7,063	1,506	347	8,916	79.2%	16.9%	3.9%	5,018,168	2,106,742	193,801	7,318,711	68.6%	28.8%	2.6%
Inpatient Visits	29,656	7,246	1,887	38,789	76.5%	18.7%	4.9%	5,811,718	1,794,897	319,252	7,925,868	73.3%	22.6%	4.0%
Lab & Pathology	200,662	106,043	12,354	319,059	62.9%	33.2%	3.9%	5,274,372	6,873,920	392,761	12,541,053	42.1%	54.8%	3.1%
Maternity	27,742	12,424	1,524	41,690	66.5%	29.8%	3.7%	6,233,473	2,164,412	291,469	8,689,353	71.7%	24.9%	3.4%
Office Visits	698,064	40,152	29,836	768,052	90.9%	5.2%	3.9%	62,776,316	4,458,531	2,905,817	70,140,664	89.5%	6.4%	4.1%
Other Services	426,788	86,662	18,749	532,200	80.2%	16.3%	3.5%	70,216,845	28,612,185	5,070,464	103,899,494	67.6%	27.5%	4.9%
Outpatient Surgery	140,126	9,142	6,319	155,587	90.1%	5.9%	4.1%	20,767,308	2,649,850	1,543,152	24,960,311	83.2%	10.6%	6.2%
Psychiatric / Substance Abuse	170,998	13,428	3,800	188,226	90.8%	7.1%	2.0%	18,860,121	1,224,455	289,233	20,373,809	92.6%	6.0%	1.4%
Radiology	193,682	16,006	8,192	217,880	88.9%	7.3%	3.8%	9,793,462	1,487,953	1,111,730	12,393,145	79.0%	12.0%	9.0%
Therapies	182,524	5,318	7,898	195,739	93.2%	2.7%	4.0%	16,437,496	340,748	479,415	17,257,659	95.2%	2.0%	2.8%
TOTAL	2,348,691	318,841	100,369	2,767,901	84.9%	11.5%	3.6%	246,370,954	55,939,795	14,573,198	316,883,947	77.7%	17.7%	4.6%
OTHER														
Ambulance	6,484	815	282	7,581	85.5%	10.8%	3.7%	3,085,165	1,101,465	160,774	4,347,404	71.0%	25.3%	3.7%
Appliances (DME)	25,131	3,924	717	29,771	84.4%	13.2%	2.4%	3,324,469	1,460,287	70,750	4,855,506	68.5%	30.1%	1.5%
TOTAL	31,615	4,739	999	37,353	84.6%	12.7%	2.7%	6,409,634	2,561,752	231,524	9,202,910	69.6%	27.8%	2.5%
GRAND TOTAL	2,888,044	358,017	119,831	3,365,892	85.8%	10.6%	3.6%	492,277,715	129,984,060	51,255,265	673,517,040	73.1%	19.3%	7.6%

**West Virginia PEIA Non-Medicare Prescription Drugs Total
Study Period of July 2017 to June 2021
(Paid Claims)**

24 Month Trends Summary

	<u>Utilization</u>	<u>Cost / Prescription</u>	<u>Total Trend</u>
Non-Medicare	0.3%	12.8%	13.1%

36 Month Trends Summary

	<u>Utilization</u>	<u>Cost / Prescription</u>	<u>Total Trend</u>
Non-Medicare	2.0%	11.5%	13.8%

48 Month Trends Summary

	<u>Utilization</u>	<u>Cost / Prescription</u>	<u>Total Trend</u>
Non-Medicare	6.6%	11.1%	18.5%


Appendix A



NON-MEDICARE CLAIMS
Excluding Drugs
GRAND TOTAL

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
3.2%	7.3%	10.7%

36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
5.3%	2.7%	8.1%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
4.3%	2.2%	6.6%





NON-MEDICARE CLAIMS
Excluding Drugs


HOSPITAL INPATIENT

TOTAL


24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
5.9%	-1.9%	3.8%

36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
6.2%	-0.5%	5.7%


48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
1.1%	-0.5%	0.5%



Total Hospital Inpatient Claims - Excluding Drugs



Total Hospital Inpatient Claims - Excluding Drugs



NON-MEDICARE CLAIMS
Excluding Drugs


HOSPITAL OUTPATIENT

TOTAL


24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-3.7%	11.4%	7.3%

36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
5.8%	3.9%	9.9%


48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
6.7%	3.4%	10.3%



Total Hospital Outpatient Claims - Excluding Drugs



Total Hospital Outpatient Claims - Excluding Drugs



NON-MEDICARE CLAIMS
Excluding Drugs


PHYSICIAN SERVICES

TOTAL


24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
7.7%	7.3%	15.5%

36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
4.7%	3.1%	7.9%


48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
3.9%	2.3%	6.3%



Total Physician Services Claims - Excluding Drugs



Total Physician Services Claims - Excluding Drugs



NON-MEDICARE CLAIMS
Excluding Drugs


OTHER

TOTAL


24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-8.4%	12.8%	3.3%

36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
1.1%	1.0%	2.1%


48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
1.2%	1.2%	2.4%



Total Other Claims - Excluding Drugs



Total Other Claims - Excluding Drugs



NON-MEDICARE CLAIMS
Excluding Drugs

HOSPITAL INPATIENT


Maternity

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-5.0%	17.9%	12.0%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
2.5%	10.1%	12.9%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
3.5%	0.0%	3.5%


Hospital Inpatient - Maternity



Hospital Inpatient - Maternity



Hospital Inpatient - Maternity



NON-MEDICARE CLAIMS
Excluding Drugs


HOSPITAL INPATIENT

Medical / Surgical


24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
7.2%	-3.9%	3.0%

36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
6.6%	-1.1%	5.4%


48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
0.9%	-0.5%	0.4%



Hospital Inpatient - Medical / Surgical



Hospital Inpatient - Medical / Surgical



NON-MEDICARE CLAIMS
Excluding Drugs

HOSPITAL INPATIENT


Psychiatric / Substance Abuse

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-5.9%	5.1%	-1.1%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
5.0%	-8.1%	-3.6%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
0.0%	-2.8%	-2.8%


Hospital Inpatient - Psychiatric / Substance Abuse



Hospital Inpatient - Psychiatric / Substance Abuse



Hospital Inpatient - Psychiatric / Substance Abuse



NON-MEDICARE CLAIMS
Excluding Drugs

HOSPITAL OUTPATIENT


Emergency Room

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-22.8%	14.4%	-11.7%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-8.8%	6.5%	-2.9%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-4.8%	5.2%	0.1%


Hospital Outpatient - Emergency Room



Hospital Outpatient - Emergency Room



Hospital Outpatient - Emergency Room



NON-MEDICARE CLAIMS
Excluding Drugs

HOSPITAL OUTPATIENT


Medical / Surgical

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
2.1%	14.7%	17.1%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
10.6%	-0.2%	10.4%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
11.4%	-2.2%	8.9%


Hospital Outpatient - Medical / Surgical



Hospital Outpatient - Medical / Surgical



Hospital Outpatient - Medical / Surgical



NON-MEDICARE CLAIMS
Excluding Drugs

HOSPITAL OUTPATIENT


Other Services

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-3.7%	6.5%	2.6%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
5.7%	7.5%	13.7%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
5.8%	9.4%	15.7%


Hospital Outpatient - Other Services



Hospital Outpatient - Other Services



Hospital Outpatient - Other Services



NON-MEDICARE CLAIMS
Excluding Drugs

HOSPITAL OUTPATIENT


Psychiatric / Substance Abuse

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
14.2%	11.1%	26.8%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
16.7%	15.3%	34.5%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
15.2%	17.5%	35.3%


Hospital Outpatient - Psychiatric / Substance Abuse



Hospital Outpatient - Psychiatric / Substance Abuse



Hospital Outpatient - Psychiatric / Substance Abuse



NON-MEDICARE CLAIMS
Excluding Drugs

PHYSICIAN SERVICES


Anesthesia

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
69.6%	-25.9%	25.6%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
31.4%	-12.1%	15.4%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
16.8%	-7.2%	8.3%


Physician Services - Anesthesia



Physician Services - Anesthesia



Physician Services - Anesthesia



NON-MEDICARE CLAIMS
Excluding Drugs

PHYSICIAN SERVICES


Chemotherapy / Radiation

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-19.0%	6.6%	-13.7%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-9.0%	0.3%	-8.7%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-4.1%	-4.5%	-8.4%


Physician Services - Chemotherapy Radiation



Physician Services - Chemotherapy Radiation



Physician Services - Chemotherapy Radiation



NON-MEDICARE CLAIMS
Excluding Drugs

PHYSICIAN SERVICES


Emergency Room

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-10.5%	5.4%	-5.6%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-9.3%	4.0%	-5.7%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-5.5%	2.8%	-2.9%


Physician Services - Emergency Room



Physician Services - Emergency Room



Physician Services - Emergency Room



NON-MEDICARE CLAIMS
Excluding Drugs

PHYSICIAN SERVICES


Immunizations / Injections / Allergy

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-28.3%	21.6%	-12.8%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-16.0%	12.8%	-5.3%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-6.4%	10.4%	3.3%


Physician Services - Immunizations / Allergy



Physician Services - Immunizations / Allergy



Physician Services - Immunizations / Allergy



NON-MEDICARE CLAIMS
Excluding Drugs

PHYSICIAN SERVICES


Inpatient Surgery

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-0.3%	8.2%	7.9%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
1.3%	-1.1%	0.1%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-0.1%	-1.8%	-1.9%


Physician Services - Inpatient Surgery



Physician Services - Inpatient Surgery



Physician Services - Inpatient Surgery



NON-MEDICARE CLAIMS
Excluding Drugs

PHYSICIAN SERVICES


Inpatient Visits

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
10.2%	5.7%	16.5%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
5.3%	0.9%	6.2%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
3.9%	-0.9%	2.9%


Physician Services - Inpatient Visits



Physician Services - Inpatient Visits



Physician Services - Inpatient Visits



NON-MEDICARE CLAIMS
Excluding Drugs

PHYSICIAN SERVICES


Lab & Pathology

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
2.8%	2.6%	5.4%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-0.4%	-5.4%	-5.8%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-0.9%	-4.4%	-5.3%


Physician Services - Lab & Pathology



Physician Services - Lab & Pathology



Physician Services - Lab & Pathology



NON-MEDICARE CLAIMS
Excluding Drugs


PHYSICIAN SERVICES

Maternity


24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
19.7%	-5.3%	13.3%

36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
15.8%	-2.5%	12.9%


48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
10.8%	-1.2%	9.5%



Physician Services - Maternity



Physician Services - Maternity



NON-MEDICARE CLAIMS
Excluding Drugs


PHYSICIAN SERVICES

Office Visits


24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
0.6%	13.8%	14.5%

36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-1.1%	4.0%	2.8%


48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-0.9%	2.0%	1.1%



Physician Services - Office Visits



Physician Services - Office Visits



NON-MEDICARE CLAIMS
Excluding Drugs


PHYSICIAN SERVICES

Other Services


24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
6.4%	8.7%	15.6%

36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
6.5%	7.5%	14.4%


48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
5.9%	7.0%	13.3%



Physician Services - Other Services



Physician Services - Other Services



NON-MEDICARE CLAIMS
Excluding Drugs

PHYSICIAN SERVICES


Outpatient Surgery

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
16.6%	-1.7%	14.6%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
9.5%	-5.8%	3.2%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
6.2%	-4.2%	1.8%


Physician Services - Outpatient Surgery



Physician Services - Outpatient Surgery



Physician Services - Outpatient Surgery



NON-MEDICARE CLAIMS
Excluding Drugs

PHYSICIAN SERVICES


Psychiatric / Substance Abuse

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
13.3%	19.2%	35.0%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
14.2%	5.9%	20.9%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
13.9%	2.5%	16.7%


Physician Services - Psychiatric / Substance Abuse



Physician Services - Psychiatric / Substance Abuse



Physician Services - Psychiatric / Substance Abuse



NON-MEDICARE CLAIMS
Excluding Drugs


PHYSICIAN SERVICES

Radiology


24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
2.9%	4.4%	7.4%

36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-1.9%	4.4%	2.4%


48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
0.1%	2.5%	2.6%



Physician Services - Radiology



Physician Services - Radiology



NON-MEDICARE CLAIMS
Excluding Drugs

PHYSICIAN SERVICES


Therapies

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
8.3%	3.7%	12.4%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
5.3%	2.6%	8.0%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
6.1%	1.9%	8.1%


Physician Services - Therapies



Physician Services - Therapies



Physician Services - Therapies



NON-MEDICARE CLAIMS
Excluding Drugs

OTHER


Ambulance

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-11.7%	-0.2%	-11.9%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-3.0%	-5.8%	-8.6%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
0.0%	-4.1%	-4.1%


Other - Ambulance



Other - Ambulance



Other - Ambulance



NON-MEDICARE CLAIMS
Excluding Drugs

OTHER


Appliances (DME)

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-5.3%	25.3%	18.6%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
5.3%	8.2%	13.9%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
2.6%	6.8%	9.6%


Other - Appliances (DME)



Other - Appliances (DME)



Other - Appliances (DME)




Appendix B


Non-Medicare Prescription Drugs

	<u>Utilization</u>	<u>Cost / Prescription</u>	<u>Total Trend</u>
24-Month Trend	0.3%	12.8%	13.1%
36-Month Trend	2.0%	11.5%	13.8%
48-Month Trend	6.6%	11.1%	18.5%


Non-Medicare Prescription Drugs



Non-Medicare Prescription Drugs



Non-Medicare Prescription Drugs



Appendix C – Prescription Drug Trends

Overview

Continuing Care Actuaries analyzed prescription drug experience provided by CVS in aggregate, by major indicator and in particular, specialty drugs. We analyzed the prescription drug trends using a 24, 36, and 48 month actuarial basis. We found the 24 month basis as the methodology that is most likely to produce accurate future trends. Under this methodology, utilization had a 0.3% trend and unit cost had a 14.2% trend, resulting in a composite trend of 12.7% on an unadjusted basis. The chart below summarizes components of the unadjusted prescription drug trend for the past 9 years.

Year	Utilization	Unit Cost	Composite Trend
2012	-0.5%	5.4%	5.6%
2013	0.0%	-5.8%	-5.5%
2014	-1.5%	6.2%	4.5%
2015	3.9%	7.9%	11.5%
2016	-0.7%	8.7%	6.9%
2017	-2.4%	12.2%	7.1%
2018	-29.0%	44.0%	2.3%
2019	-1.1%	13.4%	10.3%
2020	2.2%	7.8%	8.4%
2021	0.3%	14.2%	12.7%

Prior to this analysis, the financial plan was developed using a 13.5% trend for fiscal year 2022. Based on results and future expectations, Continuing Care Actuaries has chosen to use a gross drug trend assumption of 13.5% and drug rebate trend of 15.0% for fiscal year 2022 in the financial plan.

Brand Patent Expirations

This drug trend assumption has been made in consideration of recent drug experience, as well as future blockbuster drugs that are expected to lose their patent in the upcoming years. Overall, we can expect fewer expirations than PEIA has experienced in the past. Examples of these drugs include:

Drug	Patent Expiration	2020 Ingredient Cost		2021 Ingredient Cost	
		Amount	%	Amount	%
Januvia	2022	7,817,385	2.6%	7,893,919	2.3%
Janumet	2022	1,599,059	0.5%	1,453,731	0.4%
Vimpat	2022	553,574	0.2%	658,028	0.2%
Entresto	2023	1,141,394	0.4%	1,372,013	0.4%
Promacta	2023	874,191	0.3%	783,585	0.2%
Patanase	2023	201	0.0%	285	0.0%
Total		\$11,985,804	4.0%	\$12,161,561	3.6%

Specialty Drugs

Specialty drugs have continued to be a concern for PEIA due to the relatively rapid growth in utilization and unit cost. Nationally, specialty drug spend is approximately 50% of all drug spend. For PEIA, it is approximately 35% of all drug spend. The following chart shows the percent of plan drug expenditures in specialty drugs in the past few years. The days supply increased by 10.9% in 2021, which is a better measure of utilization.

Period	Specialty Drugs				
	Total Specialty Cost (\$M)	Percent of Total Cost	Specialty Cost Growth	Number of Specialty Rx	Specialty Rx Growth
FY 2013	\$34.0	18.00%	24.30%	11,167	5.50%
FY 2014	\$35.8	18.60%	5.30%	10,938	-2.10%
FY 2015	\$40.2	18.70%	12.40%	11,028	0.80%
FY 2016	\$48.5	21.10%	20.70%	11,128	0.90%
FY 2017	\$73.6	29.90%	51.50%	17,731	59.30%
FY 2018	\$78.3	31.30%	6.50%	16,153	-8.90%
FY 2019	\$88.8	31.98%	13.35%	17,354	7.44%
FY 2020	\$100.5	33.41%	13.21%	20,210	16.46%
FY 2021	\$118.7	35.00%	18.06%	21,863	8.18%

The following chart shows the top 10 brand name specialty drugs and their total cost in 2021:

2021 Rank	2021 Brand Name	2020 Cost	2021 Cost	Total Growth
1	HUMIRA	\$24,427,220	\$24,089,084	-1.38%
2	STELARA	\$3,401,820	\$6,982,719	105.26%
3	OTEZLA	\$3,625,653	\$4,739,614	30.72%
4	COSENTYX SENSOREADY PEN	\$0	\$4,727,971	N/A
5	ENBREL SURECLICK	\$0	\$4,289,008	N/A
6	TALTZ	\$2,530,758	\$4,088,435	61.55%
7	DUPIXENT	\$0	\$3,603,080	N/A
8	REVLIMID	\$3,549,281	\$3,465,272	-2.37%
9	HUMIRA	\$24,427,220	\$3,283,317	-86.56%
10	SKYRIZI	\$1,029,138	\$2,894,636	181.27%
	Total	\$62,991,091	\$62,163,137	-1.31%
	Percent of Specialty Cost	62.65%	52.37%	

Indicator Categories

Continuing Care Actuaries reviewed the individual prescription data items for Fiscal Years 2020 and 2021. A total of 1,917,017 scripts were written for approximately 2,530 different kinds of prescriptions in 2021. The prescriptions were grouped by indicator codes, providing a basis to develop the Fiscal Year 2021 trend by indicator code. The top 40 indicator codes were analyzed, which accounted for 87.6% of PEIA's prescription drug expenditures.

The top 5 indicators from 2021 were the same as the top 5 in 2020. The top 5 indicators all had material increases in cost. PEIA members continue to spend the most on Antirheumatic Drugs. The following chart lists the top 5 and the total drug spend each year.

Rank	2020 Indicator	2020 Cost	2021 Indicator	2021 Cost
1	ANTIRHEUMATIC	\$39,966,916	ANTIRHEUMATIC	\$46,382,858
2	INSULINS	28,980,881	INSULINS	29,115,666
3	INCRETIN MIMETI	22,354,917	INCRETIN MIMETI	29,111,373
4	ANTINEOPLASTIC	17,925,942	SKIN AND MUCOUS	27,429,495
5	SKIN AND MUCOUS	16,878,122	ANTINEOPLASTIC	20,259,573

The charts on the next few pages summarize the utilization and cost per service for formulary and non-formulary drugs for each indicator code. The "Top Five Increases in Drug Trends" chart is calculated with indicators which grossed at least \$200,000 in ingredient cost in 2021.

On pages C-6 and C-7, we list the top 40 indicators and summarize the utilization and cost statistics. These top 40 indicators represent 87.3% of total program costs.

On page C-12, we list the top 20 drugs and summarize the formulary and non-formulary cost statistics. These top 20 drugs represent 40% of total program costs.

On pages C-15 to C-19 we show a detailed analysis concerning the top 5 indicators. These analyses include drugs with the highest total ingredient cost, the amount per script, and a breakout of how much was spent on generic, formulary, and non-formulary drugs.

Indicators with the Largest Dollar Increase

Indication	2020 Total Ingredient Cost	2021 Total Ingredient Cost	Total Increase
SKIN AND MUCOUS	\$16,878,122	\$27,429,495	\$10,551,373
INCRETIN MIMETI	\$22,354,917	\$29,111,373	6,756,456
ANTIRHEUMATIC	\$39,966,916	\$46,382,858	6,415,942
ANTIDIABETIC	\$11,975,723	\$14,614,238	2,638,515
ANTINEOPLASTIC	\$17,925,942	\$20,259,573	2,333,632

Indicators with the Largest Increase as a Percentage

Indication	2020 Total Ingredient Cost	2021 Total Ingredient Cost	Total Increase
VESICULAR MONOAMINE TRANSPORTER 2 (VMAT2) INHIBITO	\$41,090	\$417,145	915.2%
INTERLEUKIN ANTAGONISTS	\$74,719	\$551,603	638.2%
AMMONIA DETOxic	\$243,497	\$688,569	182.8%
EENT DRUGS, MIS	\$114,520	\$281,923	146.2%
WAKEFULNESS	\$316,412	\$698,714	120.8%

Indicators with the Largest Increase in Claim Numbers

Indication	2020 Prescriptions	2021 Prescriptions	Utilization Increase
ANTIDEPRESSANTS	147,942	158,500	10,558
ANXIOLYTICS, SE	41,353	47,115	5,762
PPI	68,109	72,812	4,703
INCRETIN MIMETI	11,689	14,869	3,180
HMG-COA RED INH	85,768	88,105	2,337

Indicators with the Largest Utilization Increase Percentage

Indication	2020 Prescriptions	2021 Prescriptions	Utilization Increase
INTERLEUKIN ANTAGONISTS	21	135	542.9%
VESICULAR MONOAMINE TRANSPORTER 2 (VMAT2) INHIBITO	14	58	314.3%
ANTIMIGRAINE	829	1,470	77.3%
CALCITONIN GENE-RELATED PEPTIDE (CGRP) ANTAGONISTS	1,745	2,815	61.3%
CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATO	127	178	40.2%

Indicators with the Largest Increase in Cost per Prescription

Indication	2020 Ingredient Cost Per Prescription	2021 Ingredient Cost Per Prescription	Ingredient Cost Per Prescription Increase
VESICULAR MONOAMINE TRANSPORTER 2 (VMAT2) INHIBITO	\$2,934.97	\$7,192.15	\$4,257.18
VASOPRSN ANTAGO	\$13,943.41	\$15,291.57	\$1,348.15
EENT DRUGS, MIS	\$734.10	\$2,042.92	\$1,308.82
OTHER MISC THER	\$2,921.00	\$4,157.21	\$1,236.21
SKIN AND MUCOUS	\$2,028.13	\$2,891.58	\$863.44

Indicators with the Largest Percentage Increase in Cost per Prescription

Indication	2020 Ingredient Cost Per Prescription	2021 Ingredient Cost Per Prescription	Ingredient Cost Per Prescription Increase
EENT DRUGS, MIS	\$734.10	\$2,042.92	178.3%
VESICULAR MONOAMINE TRANSPORTER 2 (VMAT2) INHIBITO	\$2,934.97	\$7,192.15	145.1%
AMMONIA DETOxic	\$372.32	\$862.87	131.8%
WAKEFULNESS	\$194.12	\$390.34	101.1%
HIST H2-ANTAG	\$13.07	\$20.83	59.3%

Drug Indicators by Highest Cost

<u>Rank</u>	<u>Indicator</u>	<u>Number of Prescriptions</u>	<u>Cost Per Prescription</u>	<u>Program Costs</u>	<u>Formulary Percent (cost)</u>	<u>Formulary Percent (Scripts)</u>
1	ANTIRHEUMATIC	8,573	\$5,410.34	\$46,382,858	96.3%	95.7%
2	INSULINS	17,643	\$1,650.27	\$29,115,666	99.9%	99.9%
3	INCRETIN MIMETI	14,869	\$1,957.86	\$29,111,373	100.0%	100.0%
4	SKIN AND MUCOUS	8,546	\$2,107.43	\$18,010,062	76.1%	89.4%
5	ANTINEOPLASTIC	7,886	\$2,569.06	\$20,259,573	60.5%	91.3%
6	ANTIDIABETIC	10,928	\$1,337.32	\$14,614,238	99.8%	99.6%
7	IMMUNOMOD AGNTS	1,643	\$7,294.75	\$11,985,274	96.9%	97.0%
8	DDP-4 INHIBITOR	8,172	\$1,245.29	\$10,176,517	99.9%	99.8%
9	ANTICOAGULANTS	13,162	\$674.49	\$8,877,632	99.9%	99.8%
10	ADRENALS	56,934	\$147.08	\$8,373,897	99.1%	99.6%
11	ANTIPSYCHOTICS	11,018	\$512.04	\$5,641,656	85.7%	97.0%
12	ANTIDEPRESSANTS	158,500	\$33.57	\$5,321,373	95.4%	99.8%
13	AMPHETAMINES	24,451	\$200.72	\$4,907,718	97.9%	96.8%
14	MISC ANTICONVUL	48,270	\$101.00	\$4,875,417	85.1%	99.2%
15	NERVOUS SYS AGT	3,156	\$1,544.08	\$4,873,121	21.4%	91.3%
16	B-ADREN AGON	26,696	\$162.30	\$4,332,861	99.5%	99.8%
	CYSTIC FIBROSIS TRANSMEMBRANE					
17	CONDUCTANCE REGULATO	178	\$24,037.39	\$4,278,655	0.0%	0.0%
18	CONTRACEPTIVES	44,205	\$84.41	\$3,731,370	96.5%	99.4%
19	PPI	68,124	\$51.74	\$3,524,553	99.0%	100.0%
20	HMG-COA RED INH	88,105	\$40.34	\$3,554,366	99.4%	100.0%

Drug Indicators by Highest Cost (continued)

<u>Rank</u>	<u>Indicator</u>	<u>Number of Prescriptions</u>	<u>Cost Per Prescription</u>	<u>Program Costs</u>	<u>Formulary Percent (cost)</u>	<u>Formulary Percent (Scripts)</u>
21	GI DRUGS, MISCE	3,477	\$999.49	\$3,475,226	97.1%	97.6%
22	ANTIRETROVIRALS	1,379	\$2,277.26	\$3,140,345	99.3%	99.4%
23	ANTIMUSCARINICS	14,702	\$211.72	\$3,112,693	98.9%	99.6%
24	MISC ANTILIPEM	4,540	\$581.33	\$2,639,222	98.8%	98.8%
25	VASODILAT AGT	255	\$11,164.89	\$2,847,046	88.0%	85.5%
26	EENT ANTI-INFL	1,721	\$1,424.41	\$2,451,407	99.5%	98.5%
27	ANTI-INFLAMMATO	3,442	\$690.76	\$2,377,591	98.4%	98.9%
28	RESP AND CNS	11,898	\$178.54	\$2,124,319	81.1%	89.9%
29	ESTROGENS	12,194	\$191.25	\$2,332,100	97.9%	98.6%
30	CORTICOSTEROIDS	64,604	\$35.84	\$2,315,358	85.9%	99.0%
31	CALCITONIN GENE-RELATED PEPTIDE (CGRP) ANTAGONISTS	2,815	\$795.79	\$2,240,137	99.9%	99.9%
32	BETA BLOCKERS	62,746	\$34.83	\$2,185,356	99.3%	99.9%
33	ANGIOTEN 2 ANTG	44,533	\$48.51	\$2,160,109	99.5%	100.0%
34	THYROID AGENTS	55,736	\$38.63	\$2,153,248	90.4%	95.7%
35	PROTEASE INH	93	\$23,932.46	\$2,225,718	95.0%	89.2%
36	PLATELET-AGG IN	8,436	\$197.02	\$1,662,096	99.8%	100.0%
37	OTHER MISC THER	400	\$4,157.21	\$1,662,882	48.0%	44.8%
38	SOMATOTROP AGON	317	\$5,137.93	\$1,628,723	90.8%	91.2%
39	DIGESTANTS	418	\$3,746.11	\$1,565,873	99.9%	99.5%
40	VASOPRSN ANTAGO	102	\$15,291.57	\$1,559,740	0.0%	0.0%
	<u>All Other Indicators</u>	1,056,319	\$39.79	\$42,029,481	82.9%	98.1%
	Total	1,971,186	\$167.33	329,836,852	89.0%	98.5%

Drug Indicators by Highest Cost
Analysis of Formulary Distribution

Rank	Indicator	Formulary			Non-Formulary		
		Scripts	Ingredient Cost	Cost Per Script	Scripts	Ingredient Cost	Cost Per Script
1	ANTIRHEUMATIC	8,203	\$44,680,830	\$5,446.89	370	\$1,702,028	\$4,600.08
2	INSULINS	17,624	\$29,083,486	\$1,650.22	19	\$32,180	\$1,693.68
3	INCRETIN MIMETI	14,869	\$29,111,373	\$1,957.86	0	\$0	\$0.00
4	SKIN AND MUCOUS	7,639	\$13,702,436	\$1,793.75	907	\$4,307,626	\$4,749.31
5	ANTINEOPLASTIC	7,199	\$12,250,786	\$1,701.73	687	\$8,008,788	\$11,657.62
6	ANTIDIABETIC	10,886	\$14,588,808	\$1,340.14	42	\$25,430	\$605.47
7	IMMUNOMOD AGNTS	1,593	\$11,612,173	\$7,289.50	50	\$373,101	\$7,462.02
8	DDP-4 INHIBITOR	8,159	\$10,161,396	\$1,245.42	13	\$15,121	\$1,163.16
9	ANTICOAGULANTS	13,140	\$8,867,162	\$674.82	22	\$10,470	\$475.91
10	ADRENALS	56,705	\$8,299,003	\$146.35	229	\$74,894	\$327.05
11	ANTIPSYCHOTICS	10,687	\$4,835,097	\$452.43	331	\$806,559	\$2,436.73
12	ANTIDEPRESSANTS	158,185	\$5,077,133	\$32.10	315	\$244,240	\$775.37
13	AMPHETAMINES	23,669	\$4,804,318	\$202.98	782	\$103,400	\$132.23
14	MISC ANTICONVUL	47,873	\$4,151,389	\$86.72	397	\$724,028	\$1,823.75
15	NERVOUS SYS AGT	2,883	\$1,043,760	\$362.04	273	\$3,829,361	\$14,026.96
16	B-ADREN AGON	26,645	\$4,311,321	\$161.81	51	\$21,539	\$422.34
17	CYSTIC FIBROSIS	0	\$0	\$0.00	178	\$4,278,655	\$24,037.39
	TRANSMEMBRANE CONDUCTANCE REGULATO						
18	CONTRACEPTIVES	43,946	\$3,600,062	\$81.92	259	\$131,308	\$506.98
19	PPI	68,102	\$3,488,412	\$51.22	22	\$36,141	\$1,642.78
20	HMG-COA RED INH	88,072	\$3,534,186	\$40.13	33	\$20,180	\$611.52

Drug Indicators by Highest Cost
Analysis of Formulary Distribution (continued)

Rank	Indicator	Formulary			Non-Formulary		
		Scripts	Ingredient Cost	Cost Per Script	Scripts	Ingredient Cost	Cost Per Script
21	GI DRUGS, MISCE	3,393	\$3,375,932	\$994.97	84	\$99,294	\$1,182.07
22	ANTIRETROVIRALS	1,371	\$3,117,885	\$2,274.17	8	\$22,460	\$2,807.54
23	ANTIMUSCARINICS	14,636	\$3,077,624	\$210.28	66	\$35,069	\$531.35
24	MISC ANTILIPEM	4,487	\$2,607,635	\$581.15	53	\$31,587	\$595.99
25	VASODILAT AGT	218	\$2,506,247	\$11,496.54	37	\$340,800	\$9,210.81
26	EENT ANTI-INFL	1,695	\$2,438,954	\$1,438.91	26	\$12,454	\$478.99
27	ANTI-INFLAMMATO	3,405	\$2,339,086	\$686.96	37	\$38,505	\$1,040.67
28	RESP AND CNS	10,694	\$1,722,614	\$161.08	1,204	\$401,705	\$333.64
29	ESTROGENS	12,022	\$2,282,574	\$189.87	172	\$49,526	\$287.94
30	CORTICOSTEROIDS	63,989	\$1,990,028	\$31.10	615	\$325,331	\$528.99
31	CALCITONIN GENE-RELATED PEPTIDE (CGRP) ANTAGONISTS	2,813	\$2,237,201	\$795.31	2	\$2,936	\$1,467.84
32	BETA BLOCKERS	62,696	\$2,169,156	\$34.60	50	\$16,200	\$324.01
33	ANGIOTEN 2 ANTG	44,514	\$2,150,114	\$48.30	19	\$9,996	\$526.08
34	THYROID AGENTS	53,333	\$1,946,260	\$36.49	2,403	\$206,988	\$86.14
35	PROTEASE INH	83	\$2,113,989	\$25,469.75	10	\$111,730	\$11,172.96
36	PLATELET-AGG IN	8,432	\$1,659,170	\$196.77	4	\$2,925	\$731.34
37	OTHER MISC THER	179	\$798,231	\$4,459.39	221	\$864,651	\$3,912.45
38	SOMATOTROP AGON	289	\$1,478,204	\$5,114.89	28	\$150,518	\$5,375.66
39	DIGESTANTS	416	\$1,564,250	\$3,760.22	2	\$1,624	\$811.77
40	VASOPRSN ANTAGO	0	\$0	\$0.00	102	\$1,559,740	\$15,291.57
	<u>All other</u>	<u>1,036,329</u>	<u>\$34,825,956</u>	<u>\$33.61</u>	<u>19,990</u>	<u>\$7,203,526</u>	<u>\$360.36</u>
	Total	1,941,073	\$293,604,238	\$151.26	30,113	\$36,232,614	\$1,203.22

Drug Indicators by Highest Script Increase



Rank	Indicator	Formulary Cost Per Script	Non-Formulary Cost Per Script	Increase/ Decrease
59	AMMONIA DETOXIC	\$25.67	\$33,429.82	130,122%
84	AZOLES	4.35	4,389.92	100,901%
81	BIGUANIDES	9.72	5,567.24	57,158%
126	ANTIDIARRHEAL	21.55	5,089.82	23,522%
60	MUCOLYTIC AGENT	20.99	3,676.58	17,414%
93	A-ADRENARGC BLKR	26.77	1,724.99	6,344%
77	OPIATE AGONISTS	8.05	467.78	5,713%
76	PROGESTINS	46.32	2,523.99	5,349%
138	MISC ANTIPROTOZ	16.25	853.89	5,156%
69	DIHYDROPYRIDINE	14.75	749.43	4,983%
162	ANTI HISTAMINES	13.24	648.16	4,797%
166	QUINOLONES	2.78	135.53	4,767%
87	EENT DRUGS, MIS	340.47	15,024.16	4,313%
52	ANTIGOUT AGENTS	81.17	3,401.07	4,090%
82	BENZODIAZEPINES	6.96	281.15	3,937%
97	PENICILLINS	5.63	221.64	3,833%
15	NERVOUS SYS AGT	362.04	14,026.96	3,774%
	NONSTEROIDAL ANTI-INFLAMMATORY			
125	AGENTS	63.67	2,442.00	3,735%
19	PPI	51.22	1,642.78	3,107%
191	PROKINETIC AGEN	7.44	233.31	3,037%

Drug Indicators by Highest Script Increase (continued)


Rank	Indicator	Formulary Cost Per Script	Non-Formulary Cost Per Script	Increase/ Decrease
48	A/B-ADREN AGON	353.92	10,105.98	2,755%
111	ANTIESTROGENS	62.97	1,749.97	2,679%
58	CARDIAC MISC,	548.69	14,387.85	2,522%
72	ACEI	7.06	176.02	2,392%
12	ANTIDEPRESSANTS	32.10	775.37	2,316%
102	SULFONYLUREAS	15.98	360.88	2,159%
41	IMMUNOSU AGENT	203.21	4,526.59	2,128%
99	OPIATE ANTAGONI	62.73	1,336.80	2,031%
14	MISC ANTICONVUL	86.72	1,823.75	2,003%
142	ADAMANTANES	125.47	2,287.27	1,723%
153	5-ALPHA-REDUCT	21.27	369.37	1,637%
30	CORTICOSTEROIDS	31.10	528.99	1,601%
	ROENTGENOGRAPHIC AND OTHER			
219	IMAGING AGENTS	0.54	8.82	1,533%
136	MISC BETA-LACTA	624.77	9,617.38	1,439%
152	POT-SPAR DIUR	11.59	178.24	1,438%
20	HMG-COA RED INH	40.13	611.52	1,424%
65	SSRI AGONISTS	38.55	549.97	1,327%
124	DOPAMINE PRECUR	126.43	1,473.96	1,066%
73	TETRACYCLINES	27.39	318.85	1,064%
151	B-ADREN BLK AGT	71.32	795.09	1,015%
	<u>All Other Indicators</u>	<u>33.61</u>	<u>360.36</u>	<u>972%</u>
	Total	\$151.26	\$1,203.22	695%

Drugs by Highest Cost
Analysis of Formulary Distribution


Rank	Drug	Formulary			Non-Formulary		
		Scripts	Ingredient Cost	Cost Per Script	Scripts	Ingredient Cost	Cost Per Script
1	HUMIRA	3,754	\$24,089,084	\$6,417	0	\$0	N/A
2	TRULICITY	6,915	13,988,649	2,023	0	\$0	N/A
3	OZEMPIC	5,400	10,008,336	1,853	0	\$0	N/A
4	TRESIBA FLEXTouch	4,938	8,930,072	1,808	0	\$0	N/A
5	JANUVIA	6,291	7,893,919	1,255	0	\$0	N/A
6	FARXIGA	5,125	7,010,319	1,368	0	\$0	N/A
7	STELARA	341	6,982,719	20,477	0	\$0	N/A
8	JARDIANCE	4,875	6,422,004	1,317	0	\$0	N/A
9	NOVOLOG FLEXPEN	3,766	6,391,377	1,697	0	\$0	N/A
10	ELIQUIS	6175	5,341,581	865	0	\$0	N/A
11	OTEZLA	1,316	4,739,614	3,602	0	\$0	N/A
12	COSENTYX SENSOREADY PEN	760	4,727,971	6,221	0	\$0	N/A
13	ENBREL SURECLICK	761	4,289,008	5,636	0	\$0	N/A
14	TALTZ	0	0	N/A	612	\$4,088,435	6,680
15	VICTOZA	1,820	4,044,052	2,222	0	\$0	N/A
16	LEVEMIR FLEXTouch	2,527	3,787,854	1,499	0	\$0	N/A
17	TRIKAFTA	0	0	N/A	152	\$3,700,856	24,348
18	NOVOLOG	1671	3,611,751	2,161	0	\$0	N/A
19	DUPIXENT	1142	3,603,080	3,155	0	\$0	N/A
20	REVLIMID	232	3,465,272	14,937	0	\$0	N/A
	<u>All Other Indicators</u>	<u>1,834,450</u>	<u>174,057,715</u>	<u>95</u>	<u>23,994</u>	<u>\$27,949,652</u>	<u>1,165</u>
	Total	1,892,259	\$303,384,378	\$160.33	24,758	\$35,738,943	\$1,443.53



Ingredient Cost per Prescription



Number of Prescriptions per Member



1 – Antirheumatic Drugs

In FY 2021, the Antirheumatic Drugs category was first in cost to PEIA with expenditure of \$46,382,858, which accounted for 13.7% of total expenditures. Formulary expenditures were \$44,680,830 or 96.3% of Antirheumatic Drugs expenditures and total expenditures had a 16.4% trend from 2020 to 2021.

Drug	Current Formulary Status	Current Brand/ Generic	Number of Prescriptions			Ingredient Cost Per Prescription			Total Ingredient Cost		
			2020	2021	Growth	2020	2021	Growth	2020	2021	Growth
HUMIRA	PREF	SSB	4,063	3,754	-7.6%	\$6,012.11	\$6,416.91	6.7%	\$24,427,220	\$24,089,084	-1.4%
OTEZLA	PREF	SSB	1,216	1,316	8.2%	5,230.19	3,601.53	-31.1%	6,359,909	4,739,614	-25.5%
ENBREL SURECLICK	PREF	SSB	1,070	761	-28.9%	3,388.46	5,636.02	66.3%	3,625,653	4,289,008	18.3%
HUMIRA	PREF	SSB	557	486	-12.7%	4,558.14	6,755.80	48.2%	2,538,882	3,283,317	29.3%
XELJANZ XR	PREF	SSB	125	457	265.6%	5,133.99	4,780.38	-6.9%	641,749	2,184,633	240.4%
<u>Subtotals</u>											
Generic	Y	GEN	312	356	14.1%	\$247.85	\$246.50	-0.5%	\$77,330	87,754	13.5%
Formulary Brand	Y	Brand	7,270	7,847	7.9%	5,276.88	5,682.82	7.7%	38,362,935	44,593,076	16.2%
<u>Non-Formulary Brand</u>	<u>N</u>	<u>Brand</u>	<u>331</u>	<u>370</u>	<u>11.8%</u>	<u>4,612.24</u>	<u>4,600.08</u>	<u>-0.3%</u>	<u>1,526,651</u>	<u>1,702,028</u>	<u>11.5%</u>
Total			7,913	8,573	8.3%	\$5,050.79	\$5,410.34	7.1%	\$39,966,916	\$46,382,858	16.1%
Trends Adjusted for Exposure					8.6%			7.1%			16.4%

2 - Insulins

In FY 2021, the Insulins category was second in cost to PEIA with expenditure of \$29,115,666, which accounted for 8.6% of total expenditures overall. Formulary expenditures were \$29,083,486 or 99.9% of Insulins expenditures and total ingredient cost had a 0.5% trend from 2020 to 2021.

Drug	Current Formulary Status	Current Brand/ Generic	Number of Prescriptions			Ingredient Cost Per Prescription			Total Ingredient Cost		
			2020	2021	Growth	2020	2021	Growth	2020	2021	Growth
TRESIBA FLEXTOUCH	PREF	SSB	5,028	4,938	-1.8%	\$1,749.82	\$1,808.44	3.3%	\$8,798,117	\$8,930,072	1.5%
NOVOLOG FLEXPEN	PREF	SSB	3,743	3,766	0.6%	1,670.98	1,697.13	1.6%	6,254,482	6,391,377	2.2%
LEVEMIR FLEXTOUCH	PREF	SSB	2,528	2,527	0.0%	1,551.06	1,498.95	-3.4%	3,921,086	3,787,854	-3.4%
NOVOLOG	PREF	SSB	1,771	1,671	-5.6%	2,098.12	2,161.43	3.0%	3,715,777	3,611,751	-2.8%
BASAGLAR KWIKPEN	PREF	SSB	2,629	2,826	7.5%	915.27	883.26	-3.5%	2,406,252	2,496,099	3.7%
<u>Subtotals</u>											
Generic	Y	GEN	0	0	NA	NA	NA	NA	\$0	0	NA
Formulary Brand	Y	Brand	17,611	17,624	0.1%	1,642.31	1,650.22	0.5%	28,922,689	29,083,486	0.6%
<u>Non-Formulary Brand</u>	<u>N</u>	<u>Brand</u>	<u>37</u>	<u>19</u>	<u>-48.6%</u>	<u>1,572.76</u>	<u>1,693.68</u>	<u>7.7%</u>	<u>58,192</u>	<u>32,180</u>	<u>-44.7%</u>
Total			17,648	17,643	0.0%	\$1,642.16	\$1,650.27	0.5%	\$28,980,881	\$29,115,666	0.5%
Trends Adjusted for Exposure					0.0%			0.5%			0.5%

3 - Incretin Mimetic Drugs

In FY 2021, the Incretin Mimetic Drugs indicator category was third in cost to PEIA with expenditure of \$29,111,373, which accounted for 8.6% of total expenditures. Formulary expenditures were \$29,111,373 or 100.0% of Incretin Mimetic Drugs' expenditures. Total expenditures had a 31.2% trend from 2020 to 2021.

Drug	Current Formulary Status	Current Brand/ Generic	Number of Prescriptions			Ingredient Cost Per Prescription			Total Ingredient Cost		
			2020	2021	Growth	2020	2021	Growth	2020	2021	Growth
TRULICITY	PREF	SSB	6,116	6,915	13.1%	\$1,927.55	\$2,022.94	4.9%	\$11,788,886	\$13,988,649	18.7%
OZEMPIC	PREF	SSB	3,381	5,400	59.7%	1,753.02	1,853.40	5.7%	5,926,955	10,008,336	68.9%
VICTOZA	PREF	SSB	2,153	1,820	-15.5%	2,134.98	2,222.01	4.1%	4,596,622	4,044,052	-12.0%
RYBELSUS	PREF	SSB	28	633	2160.7%	1,097.01	1,493.74	36.2%	30,716	945,538	2978.3%
SAXENDA	PREF	SSB	0	100	NA	NA	1,224.68	NA	0	122,468	NA
<u>Subtotals</u>											
Generic	Y	GEN	0	0	NA	NA	NA	NA	\$0	0	NA
Formulary Brand	Y	Brand	11,678	14,869	27.3%	1,913.27	1,957.86	2.3%	22,343,179	29,111,373	30.3%
<u>Non-Formulary Brand</u>	<u>N</u>	<u>Brand</u>	<u>11</u>	<u>0</u>	<u>-100.0%</u>	<u>1,067.10</u>	<u>NA</u>	<u>NA</u>	<u>11,738</u>	<u>0</u>	<u>-100.0%</u>
Total			11,689	14,869	27.2%	\$1,912.47	\$1,957.86	2.4%	\$22,354,917	\$29,111,373	30.2%
Trends Adjusted for Exposure					28.2%			2.4%			31.2%

4 – Skin And Mucous

In FY 2021, the Skin and Mucous Drugs indicator category was fourth in cost to PEIA with expenditure of \$27,429,495, which accounted for 8.1% of total expenditures. Formulary expenditures were \$23,131,812 or 84.3% of Skin and Mucous Drugs expenditures and total expenditures had a 63.2% trend from 2020 to 2021.

Drug	Current Formulary Status	Current Brand/ Generic	Number of Prescriptions			Ingredient Cost Per Prescription			Total Ingredient Cost		
			2020	2021	Growth	2020	2021	Growth	2020	2021	Growth
STELARA	PREF	SSB	169	341	101.8%	\$20,129.11	\$20,477.18	1.7%	\$3,401,820	\$6,982,719	105.3%
COSENTYX SENSOREADY PEN	PREF	SSB	785	760	-3.2%	5,820.36	6,221.01	6.9%	4,568,986	4,727,971	3.5%
TALTZ	NFRM- PAOVR	SSB	372	612	64.5%	6,803.11	6,680.45	-1.8%	2,530,758	4,088,435	61.5%
DUPIXENT	PREF	SSB	659	1,142	73.3%	3,055.49	3,155.06	3.3%	2,013,566	3,603,080	78.9%
SKYRIZI	PREF	SSB	63	178	182.5%	16,335.53	16,262.00	-0.5%	1,029,138	2,894,636	181.3%
<u>Subtotals</u>											
Generic	Y	GEN	5,065	4,743	-6.4%	\$274.92	\$256.79	-6.6%	\$1,392,446	1,217,951	-12.5%
Formulary Brand	Y	Brand	2,574	3,861	50.0%	4,782.44	5,675.70	18.7%	12,309,990	21,913,861	78.0%
<u>Non-Formulary Brand</u>	<u>N</u>	<u>Brand</u>	<u>683</u>	<u>882</u>	<u>29.1%</u>	<u>4,649.61</u>	<u>4,872.66</u>	<u>4.8%</u>	<u>3,175,686</u>	<u>4,297,684</u>	<u>35.3%</u>
Total			8,322	9,486	14.0%	\$2,028.13	\$2,891.58	42.6%	\$16,878,122	\$27,429,495	62.5%
Trends Adjusted for Exposure					14.5%			42.6%			63.2%

5 – Antineoplastic

In FY 2021, the Antineoplastic indicator category was fifth in cost to PEIA with expenditure of \$20,259,573, which accounted for 6.0% of total expenditures. Formulary expenditures were \$12,251,015 or 60.5% of Antineoplastic expenditures and total expenditures had a 13.1% trend from 2020 to 2021.

Drug	Current Formulary Status	Current Brand/ Generic	Number of Prescriptions			Ingredient Cost Per Prescription			Total Ingredient Cost		
			2019	2020	Growth	2019	2020	Growth	2019	2020	Growth
REVLIMID	PREF	SSB	246	232	-5.7%	\$14,427.97	\$14,936.52	3.5%	\$3,549,281	\$3,465,272	-2.4%
IBRANCE	PREF	SSB	178	183	2.8%	11,991.68	12,596.39	5.0%	2,134,519	2,305,140	8.0%
IMBRUVICA	N-FORM	SSB	161	164	1.9%	11,997.17	13,257.43	10.5%	1,931,545	2,174,219	12.6%
SPRYCEL	PREF	SSB	72	101	40.3%	13,133.11	12,711.30	-3.2%	945,584	1,283,841	35.8%
LYNPARZA	PREF	SSB	9	58	544.4%	15,298.83	15,324.54	0.2%	137,689	888,823	545.5%
<u>Subtotals</u>											
Generic	Y	GEN	6,459	6,409	-0.8%	\$211.07	\$228.70	8.4%	\$1,363,305	1,465,767	7.5%
Formulary Brand	Y	Brand	629	798	26.9%	13,308.30	13,515.35	1.6%	8,370,919	10,785,248	28.8%
<u>Non-Formulary Brand</u>	<u>N</u>	<u>Brand</u>	<u>711</u>	<u>679</u>	<u>-4.5%</u>	<u>11,521.40</u>	<u>11,794.64</u>	<u>2.4%</u>	<u>8,191,717</u>	<u>8,008,558</u>	<u>-2.2%</u>
Total			7,799	7,886	1.1%	\$2,298.49	\$2,569.06	11.8%	\$17,925,942	\$20,259,573	13.0%
Trends Adjusted for Exposure					1.2%			11.8%			13.1%